Clinical Trials Logo

Amyotrophic Lateral Sclerosis clinical trials

View clinical trials related to Amyotrophic Lateral Sclerosis.

Filter by:

NCT ID: NCT04816227 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments

Mac2ALS
Start date: September 29, 2021
Phase:
Study type: Observational

The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and asymptomatic ALS gene carriers, to find new pathways for therapeutic targets and disease biomarkers.

NCT ID: NCT04800926 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Xavier Electromyographic Wheelchair Control for Limited Mobility Patients

Start date: January 11, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the functional mobility and self-reported satisfaction with the Xavier electromyography hands-free wheelchair control system in comparison with a standard joystick.

NCT ID: NCT04798378 Recruiting - Stroke Clinical Trials

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

Start date: April 16, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one arm sufficient to perform daily activities. This study could lead to the development of a product that could allow people with arm weakness or arm paralysis to use the NuroSleeve and similar devices to improve arm health and independent function.

NCT ID: NCT04798183 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Geometrical Facial Deformation According to Posture in Amyotrophic Lateral Sclerosis

Start date: March 1, 2021
Phase:
Study type: Observational

The measurement of the facial deformation according to the body posture will be conducted by 3D scanning for each posture after marking the landmarks on the face. A 3D scan of the face will be conducted for 1 minute in a static state for the sitting posture to be used as a reference, the supine posture to gaze at the ceiling while lying down correctly, and the lateral posture to the side with the upper body facing left. Healthy volunteer and ALS with bulbar palsy participants will be asked to keep their mouths closed gently while the 3D scan was being processed. A post-processing of the 3D face scan data will be conducted to analyze facial deformation by the body postures. A facial deformation will be analyzed by measuring the amount of change in position for each reference point after aligning and rotating the facial data on the same basis. The relative ratio of the amount of position change to the size of the face will be analyzed. The present study will analyze the effect of the body posture on the position changes of the landmarks.

NCT ID: NCT04797845 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Patient's TeleMonitoring With Amyotrophic Lateral Sclerosis Treated by Non Invasive Ventilation at Home.

TS-VAD
Start date: April 12, 2021
Phase: N/A
Study type: Interventional

Single-center, prospective pilot study on patients with amyotrophic lateral sclerosis fitted with noninvasive ventilation. The objective is to assess the satisfaction of remote monitoring of patients on non-invasive ventilation after 12 months.

NCT ID: NCT04788745 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

MetFlex
Start date: June 29, 2021
Phase: Phase 2
Study type: Interventional

MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).

NCT ID: NCT04768972 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Start date: June 14, 2021
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).

NCT ID: NCT04762589 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

RT001 in Amyotrophic Lateral Sclerosis

Start date: March 10, 2021
Phase: Phase 2
Study type: Interventional

RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis

NCT ID: NCT04749433 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS

Start date: September 1, 2021
Phase: Phase 1
Study type: Interventional

The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of people with amyotrophic lateral sclerosis (ALS). The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with ALS and healthy patients.

NCT ID: NCT04745299 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

ALSummit
Start date: March 23, 2021
Phase: Phase 3
Study type: Interventional

ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.